OPKO Health Inc.

Major Shareholding Notification • Aug 5, 2017

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden hours
per response	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person OPKO Health, Inc.		2. Date of Event Requiring Statement (Month/Day/Year)		3. Issuer Name and Ticker or Trading Symbol Sevion Therapeutics, Inc. [SVON]
(Last) 4400 Biscayne Blvd.	(First)	(Middle)	07/28/2017		4. Relationship of Reporting Person(s) to Issuer (Check all applicable)			5. If Amendment, Date Original Filed(Month/Day/Year)
(Street) Miami	FL	33137			_ Director _ Officer (give title below)	X 10% Owner ____ Other (specify below)		6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person
(City)	(State)	(Zip)						____ Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)				Owned (Instr. 4)	2. Amount of Securities Beneficially	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	(Instr. 5)	4. Nature of Indirect Beneficial Ownership
Common Stock					10,517,016	D

Table II - Derivative Securities Beneficially Owned ( e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Security: Direct (D) or Indirect (I) (Instr. 5)
(1) 0% Series C Convertible Perferred	(2)	(2)	Common Stock	1,250,007	\$0.4	D
(3) Warrant (Right to Buy)	05/16/2014	05/16/2019	Common Stock	6,741	\$2	D
(1) Warrant (Right to Buy)	07/27/2015	01/27/2018	Common Stock	333,333	\$1.5	D
(1) Convertible Promissory Note	02/24/2017	08/24/2017	Common Stock	2,500,000	\$0.1	D
(1) Convertible Promissory Note	11/10/2016	11/10/2017	Common Stock	1,500,000	\$0.1	D

Explanation of Responses:

• (1) The derivative security was previously subject to a "blocker" pursuant to which the reporting person was unable to convert the derivative security to the extent such conversion would result in the reporting person owning more than 4.99%.
• (2) The convertible preferred stock is convertible at any time at the holder's option and has no expiration date.
• (3) The derivative security was previously subject to a "blocker" pursuant to which the reporting person was unable to convert the derivative security to the extent such conversion would result in the reporting person owning more than 9.99%.

Adam Logal, Chief Financial Officer 08/04/2017 **Signature of Reporting Person Date

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.